Skip to main content
Caplight Logo









Seamless Therapeutics

Seamless Therapeutics

Private
DresdenHealthcare & Life Scienceshttps://seamlesstx.com/

Last Round

Seed

Apr 23, 2024

Total Funding Raised

$37.5M

Company Overview

Seamless Therapeutics is a biotechnology company developing a gene-editing platform using programmable recombinases to create therapies for severe diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene editingrecombinase technologyprecision medicineDNA integrationgenetic medicinebiotech R&Dtherapeutic developmentgene therapymolecular engineeringbiotech licensinggenome engineeringCRISPR alternativesite-specific modificationdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Seamless Therapeutics Comparables

Compare Seamless Therapeutics with similar companies based on industry and business-model similarity.

Seamless Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stylus Medicine
82%
Brink Therapeutics
82%
Komo Biosciences
78%

Seamless Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 23, 2024
SeedMar 16, 2023

Key People

Founding team and executive leadership

Felix Lansing

Board Member, Chief Technology Officer, Co-Founder

Founding Team

Albert Seymour

President And CEO

Executive Team

Seamless Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 6, 2026

    Global agreement to develop treatments for hearing loss indications.

  • Jan 1, 2026

    Partnered to develop treatments for hearing loss in January 2026.

Seamless Therapeutics Filings

Explore SEC and related filing metadata, where available.

Seamless Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Seamless Therapeutics's valuation, stock price, and market status.

Is Seamless Therapeutics a public or private company?

Seamless Therapeutics is a private company.

What is the current stock price of Seamless Therapeutics?

Seamless Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Seamless Therapeutics worth (valuation)?

Valuation information for Seamless Therapeutics is not publicly available.

Can I buy Seamless Therapeutics stock?

Seamless Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Seamless Therapeutics's last funding round?

Seamless Therapeutics's most recent funding round was Seed on April 23, 2024.

Who are the main investors in Seamless Therapeutics?

Key investors in Seamless Therapeutics include Wellington Partners.

Will Seamless Therapeutics IPO soon?

No public IPO plans have been announced for Seamless Therapeutics.

How can I track Seamless Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Seamless Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersDresden
Employee Range28
Year Founded2022
Last FundingApr 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?